Dianthus Therapeutics, Inc. (DNTH) dividends
DNTH on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Dianthus Therapeutics, Inc. dividend: key facts
Own Dianthus Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next DNTH dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Roth Capital biotech analysts hold analyst/industry conference call12 Nov 2026 · TheFly
Biotech Analysts, along with multifocal motor neuropathy (MMN) Expert Dr. Jeffrey Allen, who discusses Dianthusâ (DNTH) and Argenxâs (ARGX) December MMN results on an Analyst/Industry conference call ...
- Dianthus reports Q3 EPS (81c), consensus (95c)5 Nov 2026 · TheFly
Reports Q3 revenue $1.21M, consensus $388,660. âThe Dianthus (DNTH) team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and...
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results5 Nov 2026 · GlobeNewsWire
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic ...
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3 Nov 2026 · GlobeNewsWire
NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
- Dianthus Therapeutics to Participate in Five Investor Conferences During November3 Nov 2026 · GlobeNewsWire
NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
- Dianthus initiated with a Buy at Roth Capital27 Oct 2026 · TheFly
Roth Capital initiated coverage of Dianthus (DNTH) with a Buy rating and $113 price target The firm believes claseprubartâs ârapidâ clinical activity, infrequent low-volume self-injection, and potenti...
- Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma17 Oct 2026 · GlobeNewsWire
NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
- Dianthus files automatic mixed securities shelf15 Oct 2026 · TheFly
16:03 EDT Dianthus (DNTH) files automatic mixed securities shelf
Insufficient verified data for a financial-health score
Dividend data and price last updated 17 Nov 2026.